Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383220 | 0.83 | TDP1 (0.36) | — | |
| SCHEMBL12391585 | 0.82 | ALDH1A1 (0.32) | ALDH1A1MAPK1 | |
| SCHEMBL12339200 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3913465 | 0.78 | MAPK1 (0.50) | ALDH1A1MAPK1 | |
| SCHEMBL5217357 | 0.78 | — | — | |
| SCHEMBL23450964 | 0.78 | — | — | |
| SCHEMBL14417056 | 0.78 | — | — | |
| SCHEMBL16772325 | 0.78 | — | — | |
| SCHEMBL2016418 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL1052630 | 0.78 | MAPK1 (0.33) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023171326-A1 | METHOD FOR PRODUCING ALKENE | 株式会社クレハ | 2023-09-14 | — | — | WO | disclosed |
| WO-2023171325-A1 | METHOD FOR PRODUCING ALKENE | 株式会社クレハ | 2023-09-14 | — | — | WO | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11691985-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| US-11186531-B2 | Production method for alkene | KUREHA CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | KUREHA CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| CN-111712480-A | Process for producing chain olefin | 株式会社吴羽 | 2020-09-25 | — | — | CN | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| EP-0004335-A2 | Prostacyclin analogs, process and intermediates for their preparation and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-03 | — | — | EP | disclosed |
| EP-0001270-A1 | Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | ALDH1A1 877/4885CYP2C19 1391/4885MAPK1 3821/4885 |
| US-11691985-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | ALDH1A1 1925/4885CYP2C19 1742/4885MAPK1 3642/4885 |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | ALDH1A1 2953/4885CYP2C19 556/4885MAPK1 836/4885 |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, NSUN2, RNMT | ALDH1A1 740/4885CYP2C19 894/4885MAPK1 3247/4885 |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | ALK, ALKBH3, ALKBH1 | ALDH1A1 299/4885CYP2C19 805/4885MAPK1 3808/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ALDH1A1 1125/4885CYP2C19 1407/4885MAPK1 3525/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | ALDH1A1 10/4885CYP2C19 42/4885MAPK1 2111/4885 |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | ALDH1A1 1160/4885CYP2C19 603/4885MAPK1 3034/4885 |
| US-11186531-B2 | Production method for alkene | ALK, ALKBH3, ALKBH1 | ALDH1A1 299/4885CYP2C19 805/4885MAPK1 3808/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | ALDH1A1 1946/4885CYP2C19 3224/4885MAPK1 3192/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | ALDH1A1 302/4885CYP2C19 1373/4885MAPK1 929/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | ALDH1A1 642/4885CYP2C19 4321/4885MAPK1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.